Pharmacokinetics and Pharmacodynamics of Vildagliptin in Healthy Chinese Volunteers

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Journal of clinical pharmacology

• Publication date

  2009-01-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1177/0091270008325152PMID 18832295
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Prevalence of Diabetes Mellitus in China

  2007cited by this paper
• Pharmacokinetics and Pharmacodynamics of Vildagliptin in Patients with Type 2 Diabetes Mellitus

  2007cited by this paper
• Efficacy and tolerability of vildagliptin monotherapy in drug-naïve patients with type 2 diabetes.

  2007cited by this paper
• Dose Proportionality and the Effect of Food on Vildagliptin, a Novel Dipeptidyl Peptidase IV Inhibitor, in Healthy Volunteers

  2007cited by this paper
• Effects of Dipeptidyl Peptidase-4 Inhibition on Gastrointestinal Function, Meal Appearance, and Glucose Metabolism in Type 2 Diabetes

  2007cited by this paper
• Pharmacodynamics of Vildagliptin in Patients With Type 2 Diabetes During OGTT

  2007cited by this paper
• The Absolute Oral Bioavailability and Population-Based Pharmacokinetic Modelling of a Novel Dipeptidylpeptidase-IV Inhibitor, Vildagliptin, in Healthy Volunteers

  2007influential reference
• Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes.

  2006cited by this paper
• PII‐12

  2006cited by this paper
• Prevalence of type 2 diabetes mellitus of Chinese populations in Mainland China, Hong Kong, and Taiwan.

  2006cited by this paper
• International Journal for Equity in Health the Burden of Non Communicable Diseases in Developing Countries

  2005cited by this paper
• (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.

  2005cited by this paper
• Improved glycaemic control with dipeptidyl peptidase‐4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response

  2005cited by this paper
• Confidence Interval Criteria for Assessment of Dose Proportionality

  2004cited by this paper
• Glycemic control and medication compliance in diabetic patients in a pharmacist-managed clinic in Hong Kong.

  2003cited by this paper
• The status of diabetes control in Asia—a cross‐sectional survey of 24 317 patients with diabetes mellitus in 1998

  2002cited by this paper
• Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients.

  2001cited by this paper
• Epidemiologic study of type 2 diabetes in Taiwan.

  2000cited by this paper
• Dipeptidyl-peptidase IV (CD26)--role in the inactivation of regulatory peptides.

  1999cited by this paper
• Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes.

  1998cited by this paper
• Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus.

  1993cited by this paper
• Glucagon-like peptide-1 7-36: a physiological incretin in man.

  1987cited by this paper
• Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses.

  1986cited by this paper
• 0021-972X/04/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 89(5):2078–2084 Printed in U.S.A. Copyright © 2004 by The Endocrine Society doi: 10.1210/jc.2003-031907 Inhibition of Dipeptidyl Peptidase-4 Reduces Glycemia, Sustains Insulin Levels

  year unknowncited by this paper

• Bioequivalence assessment between two formulations of a film-coated fixed-dose combination of metformin and vildagliptin (850/50mg) in healthy Tunisian subjects under fed conditions

  2026cites this paper
• A tumor-on-a-chip for in vitro study of CAR-T cell immunotherapy in solid tumors.

  2025cites this paper
• Hydrolysates from a Whey Protein Concentrate Are a Promising Functional Ingredient for Diabetes Control via DPP-IV Inhibition

  2025cites this paper
• Harnessing benzofuran scaffolds: A journey through design, synthesis, and biological discovery toward safer anti-diabetic and anti-oxidant candidates.

  2025cites this paper
• A Comprehensive Physiologically Based Pharmacokinetic Model for Predicting Vildagliptin Pharmacokinetics: Insights into Dosing in Renal Impairment

  2024cites this paper
• Pharmacokinetics and Bioequivalence of 2 Oral Formulations of Vildagliptin in Healthy Chinese Subjects

  2024influential citation
• Sustained-Release Vildagliptin 100 mg in Type 2 Diabetes Mellitus: A Review

  2023cites this paper
• A systematic review on the clinical pharmacokinetics of vildagliptin in healthy and disease populations

  2023cites this paper
• Pharmacokinetics and Food Effect Between a 100‐mg Sustained‐Release Tablet and a 50‐mg Immediate‐Release Tablet of Vildagliptin in Healthy Subjects

  2023cites this paper
• DPP-4 inhibitors for treating T2DM - hype or hope? an analysis based on the current literature

  2023cites this paper
• Therapeutic Effects of Switching to Anagliptin from Other DPP-4 Inhibitors in T2DM Patients with Inadequate Glycemic Control: A Non-interventional, Single-Arm, Open-Label, Multicenter Observational Study

  2022cites this paper
• Development, validation and application of a liquid chromatography-tandem mass spectrometry method for the activity and inhibition of DPP-4.

  2022cites this paper
• Opportunities and challenges of incretin-based hypoglycemic agents treating type 2 diabetes mellitus from the perspective of physiological disposition

  2022cites this paper
• Bioequivalence Study of Fixed-Dose Combination of Remogliflozin Etabonate 100 mg/Vildagliptin 50 mg with Individual Components in Healthy Indian Male Subjects under Fed Conditions

  2022cites this paper
• Clinical pharmacokinetics and pharmacodynamics of vildagliptin 50 mg sustained release tablet formulation in healthy Indian males after single and multiple-dose

  2021cites this paper
• Comparative Clinical Pharmacokinetics and Pharmacodynamics of Investigational Once-Daily Sustained-Release (SR) Vildagliptin 100 mg Tablet Formulation with Conventional 50 mg Twice-Daily Regimen in Healthy Indian Males

  2021influential citation
• Formulation of Lipid-Based Tableted Spray-Congealed Microparticles for Sustained Release of Vildagliptin: In Vitro and In Vivo Studies

  2021cites this paper
• Population Pharmacokinetic Method to Predict Within-Subject Variability Using Single-Period Clinical Data

  2021cites this paper
• Possibility of pharmacokinetic drug interaction between a DPP-4 inhibitor and a SGLT2 inhibitor

  2020cites this paper
• Simultaneous HPLC determination of vildagliptin, ampicillin, sulbactam and metronidazole in pharmaceutical dosage forms and human urine

  2020cites this paper
• Efficacy of Modern Diabetes Treatments DPP-4i, SGLT-2i, and GLP-1RA in White and Asian Patients With Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials

  2020cites this paper
• Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Korean Patients with Type 2 Diabetes Mellitus in Real-World Clinical Practice

  2019cites this paper
• DPP8 is a novel therapeutic target for multiple myeloma

  2019cites this paper
• Predictors of the Efficacy of Dipeptidyl Peptidase-4 Inhibitors in Taiwanese Patients with Type 2 Diabetes Mellitus

  2019cites this paper
• DMSO_A_220180 2725..2733

  2019cites this paper
• Vildagliptin loaded triangular DNA nanospheres coated with eudragit for oral delivery and better glycemic control in type 2 diabetes mellitus.

  2018cites this paper
• Effect of race and ethnicity on vildagliptin efficacy: A pooled analysis of phase II and III studies

  2017cites this paper
• An open-label, multiple-dose study to assess the pharmacokinetics and tolerability of sitagliptin/metformin fixed-dose combination (FDC) tablet in healthy Chinese adult subjects.

  2016cites this paper
• Application of pharmacometric approaches to evaluate effect of weight and renal function on pharmacokinetics of alogliptin.

  2016cites this paper
• Few Drugs Display Flip-Flop Pharmacokinetics and These Are Primarily Associated with Classes 3 and 4 of the BDDCS.

  2015cites this paper
• Efficacy of dipeptidyl‐peptidase‐4 inhibitors and impact on β‐cell function in Asian and Caucasian type 2 diabetes mellitus patients: A meta‐analysis在亚洲人和白种人的2型糖尿病患者中DPP‐4抑制剂的疗效及对β细胞功能的影响：一项meta分析

  2015cites this paper
• Dipeptidyl peptidase IV inhibitors: a new paradigm in type 2 diabetes treatment.

  2014cites this paper
• Incretin physiology and pathophysiology from an Asian perspective

  2014cites this paper
• DPP-4 inhibitors: pharmacological differences and their clinical implications

  2014cites this paper
• The impact of dipeptidyl peptidase 4 inhibition on incretin effect, glucose tolerance, and gastrointestinal-mediated glucose disposal in healthy subjects.

  2014cites this paper
• PNS1300360 34..46

  2014cites this paper
• Comparison of the Efficacy of Dipeptidylpeptidase-4 Inhibitors Between Asian and Non-Asian Populations

  2013cites this paper
• Characterisation of oral and i.v. glucose handling in truncally vagotomised subjects with pyloroplasty

  2013cites this paper
• Food protein hydrolysates as a source of dipeptidyl peptidase IV inhibitory peptides for the management of type 2 diabetes

  2013cites this paper
• Differential effects of vildagliptin and glimepiride on glucose fluctuations in patients with type 2 diabetes mellitus assessed using continuous glucose monitoring

  2013cites this paper
• Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis

  2013cites this paper
• Marked improvement of elderly postprandial hypotension by dipeptidyl peptidase IV inhibitor

  2013cites this paper
• Inhibition of intracellular dipeptidyl peptidases 8 and 9 enhances parthenolide’s anti-leukemic activity

  2013cites this paper
• COVALENT ENZYME INHIBITION IN DRUG DISCOVERY AND DEVELOPMENT

  2013cites this paper
• Clinical Pharmacokinetics and Pharmacodynamics of Vildagliptin

  2012influential citation
• Vildagliptin

  2012cites this paper
• DIPEPTIDYL PEPTIDASE-4 INHIBITORS AND GLUCAGON LIKE PEPTIDE-1 ANALOGS : NEWFOUNDS FOR TYPE 2 DIABETES MELLITUS

  2012cites this paper
• Mechanisms of action of the dipeptidyl peptidase‐4 inhibitor vildagliptin in humans

  2011cites this paper
• Advances in the treatment of type 2 diabetes mellitus.

  2011cites this paper
• Vildagliptin for the treatment of diabetes

  2011cites this paper
• Bioinformatic studies of the disposition pathways and targets of synthetic drugs and herbal medicines

  2011cites this paper
• Thorough QT study of the effects of vildagliptin, a dipeptidyl peptidase IV inhibitor, on cardiac repolarization and conduction in healthy volunteers

  2011cites this paper
• Therapy in prac T ice

  2011cites this paper
• Pharmacokinetics and pharmacodynamics of vildagliptin in Japanese patients with type 2 diabetes.

  2010cites this paper
• Pharmacokinetics of dipeptidylpeptidase‐4 inhibitors

  2010cites this paper
• Vildagliptin: A Review of Its Use in Type 2 Diabetes Mellitus

  2010cites this paper
• Pharmacokinetics of lipoyl vildagliptin, a novel dipeptidyl peptidase IV inhibitor after oral administration in rats

  2010cites this paper
• Systematic evaluation of dose proportionality studies in clinical pharmacokinetics.

  2010cites this paper
• Effects of miglitol, sitagliptin or their combination on plasma glucose, insulin and incretin levels in non-diabetic men.

  2010cites this paper
• Glycaemic control in type 2 diabetes: targets and new therapies.

  2010cites this paper
• mellitus by drugs modulating the incretin system

  2009cites this paper
• Oral antidiabetic drug metabolism: pharmacogenomics and drug interactions

  2009cites this paper
• DPP-4 Inhibitors in Clinical Practice

  2009cites this paper
• Vildagliptin in clinical practice: a review of literature

  2009cites this paper
• Drug, Healthcare and Patient Safety Dovepress Open Access to Scientific and Medical Research Open Access Full Text Article Dipeptidyl Peptidase-4 Inhibitors in the Management of Type 2 Diabetes: Safety, Tolerability, and Efficacy

  year unknowncites this paper